Drug continues to show promise as means to control chemotherapy’s side effects | News | Notre Dame News | University of Notre Dame






	
	





  	Skip To Content
	Skip To Navigation
	Skip To Search






  
  
    University of Notre Dame

    
      
      Notre Dame News

      
      
    


    
    
      
        
        
        	
	Experts
	ND in the News
	Subscribe
	About Us
	


      
        
          
          
          
          
          
        

      


      
    


    
    
      	 Home
	 Contact
	 Search
	
          
          
            
            
          
          Menu
        
        


      
        
          
          
          
          
          
        

      

    

  

  
  

  

  
    	Home › 
	News › 
	Drug continues to show promise as means to control chemotherapy’s side effects


    
      
        
          Drug continues to show promise as means to control chemotherapy’s side effects

          
            
              
                
                Published: September 05, 2005
              

              
                Author: William G. Gilroy
              

              







          

          
          
          

          
        
        
        
          

A team of scientists led by a University of Notre Dame cancer researcher has found further evidence that an antipsychotic drug also may help prevent chemotherapy-induced nausea and vomiting.

Rudolph M. Navari, director of Notre DamesWaltherCancerResearchCenter, has been leading a team of researchers from theIndianaUniversityand University of Kentucky Medical Schools and the Walther Cancer Institutes Hoosier Oncology Group in a study of a drug called olanzapine for the control of chemotherapys most common side effects. Olanzapine, which carries the brand name Zyprexa, has been used since the mid-1990s to treat schizophrenia and other psychoses.

In a Phase I study, the researchers found that when olanzapine was added to the standard mix of drugs used to relieve nausea and vomiting given to patients prior to receiving chemotherapy, there was essentially no nausea or vomiting in the 24-hour period following treatment. Olanzapine also prevented nausea and vomiting during the week after chemotherapy if it was given daily for two to five days.

Our recently published Phase II study reinforces the findings of the Phase I study and provides further evidence that olanzapine is safe and highly effective in controlling acute and delayed chemotherapy-induced nausea and vomiting,Navari said.The response to olazapine and control of nausea was equal or greater than in the Phase I study.

Navari points out that one class of drugs used historically to treat chemotherapy-induced nausea and vomiting is corticosteroids.

Corticoteroids can be very effective, but they have many side effects and we worry about using them for as long as five or six days,Navari said.In a recently completedbut unpublished study, we substituted olanzapine for corticosteroids and demonstrated that it was as effective in controlling nausea and vomiting without the side effects. It appears that we can probably replace corticosteroids and effectively use olanzapine for three or four days.

Navari points out that using olanzapine to control chemotherapy-induced nausea and vomiting is anoff-label usefor the antipsychotic drug.However, he notes that many drugs on the market are currently being safely used for off-label purposes.

* Contact: *  _Rudolph M. Navari, director,WaltherCancerResearchCenter, 574-631-3793, navari.1@nd.edu _

TopicID: 13104

        

        
        
          
            

          

        
      
      
    
  
  
    	Home
	Experts
	ND in the News
	Subscribe
	About Us


  

  
  
    
     
  
  

  
  
    
      	For the Media
	Contact


    
            
    
      
	Office of Public Affairs and Communications


      Notre Dame News

      
        
          
            500 Grace Hall
 
            Notre Dame, IN 46556 USA
          
          
          
          
        

        
          	 Facebook
	 Twitter
	 Instagram
	 YouTube
	 Pinterest


        
      

      
© 2022 University of Notre Dame

    
    
      

        
      
      
        
          	Search
	Mobile App
	News
	Events
	Visit
	Accessibility


        
        
          	 Facebook
	 Twitter
	 Instagram
	 YouTube
	 LinkedIn